{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Typical unilateral optic neuritis with reduced acuity and RAPD Speeds visual recovery First-line for demyelinating, MOGAD, and NMOSD optic neuritis\n\n*   **Treatment:** Oral prednisolone taper (e.g., 0.5\u20131 mg/kg for 1\u20132 weeks) after IV course\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Prevents rebound after IV steroids Standard adjunct following IV methylprednisolone in optic neuritis\n\n*   **Treatment:** Gastroprotection and metabolic monitoring during steroids (PPI, glucose checks, BP monitoring)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Mitigate steroid adverse effects Patient safety while on high-dose steroids\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve if poor visual recovery within 1\u20132 weeks Indicated for severe NMOSD/MOGAD relapses unresponsive to steroids\n\n*   **Treatment:** Disease-modifying therapy for multiple sclerosis (agent per MRI/CSF and risk profile)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate only if MS diagnosis established Prevents future relapses and disability\n\n*   **Treatment:** Rituximab-based maintenance immunotherapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start if AQP4-IgG NMOSD confirmed Reduces relapse risk\n\n*   **Treatment:** IVIG or steroid-sparing immunotherapy (e.g., mycophenolate/azathioprine) for MOGAD\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Consider if MOG-IgG positive or relapsing course Prevents further optic neuritis attacks\n\n*   **Treatment:** Antiplatelet therapy (aspirin) or anticoagulation only if ischemic optic neuropathy/vascular aetiology confirmed\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Not indicated without vascular diagnosis Avoids unnecessary bleeding risk despite thrombophilia history\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Typical unilateral optic neuritis with reduced acuity and RAPD\", \"Speeds visual recovery\", \"First-line for demyelinating, MOGAD, and NMOSD optic neuritis\"]}, {\"treatment\": \"Oral prednisolone taper (e.g., 0.5\\u20131 mg/kg for 1\\u20132 weeks) after IV course\", \"timing\": \"Start Now\", \"reasons\": [\"Prevents rebound after IV steroids\", \"Standard adjunct following IV methylprednisolone in optic neuritis\"]}, {\"treatment\": \"Gastroprotection and metabolic monitoring during steroids (PPI, glucose checks, BP monitoring)\", \"timing\": \"Start Now\", \"reasons\": [\"Mitigate steroid adverse effects\", \"Patient safety while on high-dose steroids\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve if poor visual recovery within 1\\u20132 weeks\", \"Indicated for severe NMOSD/MOGAD relapses unresponsive to steroids\"]}, {\"treatment\": \"Disease-modifying therapy for multiple sclerosis (agent per MRI/CSF and risk profile)\", \"timing\": \"Delay\", \"reasons\": [\"Initiate only if MS diagnosis established\", \"Prevents future relapses and disability\"]}, {\"treatment\": \"Rituximab-based maintenance immunotherapy\", \"timing\": \"Delay\", \"reasons\": [\"Start if AQP4-IgG NMOSD confirmed\", \"Reduces relapse risk\"]}, {\"treatment\": \"IVIG or steroid-sparing immunotherapy (e.g., mycophenolate/azathioprine) for MOGAD\", \"timing\": \"Delay\", \"reasons\": [\"Consider if MOG-IgG positive or relapsing course\", \"Prevents further optic neuritis attacks\"]}, {\"treatment\": \"Antiplatelet therapy (aspirin) or anticoagulation only if ischemic optic neuropathy/vascular aetiology confirmed\", \"timing\": \"Delay\", \"reasons\": [\"Not indicated without vascular diagnosis\", \"Avoids unnecessary bleeding risk despite thrombophilia history\"]}]"
}